2024 AANS Neurosurgical Topics for APPs - On-Demand-Malignant Tumor Management

Video Transcription

Video Summary

Dr. Adamson's presentation on malignant tumor management emphasizes the prevalence and challenges of treating glioblastomas, the most common malignant primary brain tumors. The World Health Organization's 2021 classification highlights the importance of genomic analysis for diagnosis, especially impactful given glioblastoma's aggressive nature. Despite research, standard treatment remains surgical resection followed by radiotherapy and temozolomide, extending survival to approximately 18 months. The talk also covers newer therapies like tumor treating fields and Gamma Tile, which offer marginal survival benefits but require careful consideration due to potential side effects. Metastases were discussed, exemplifying how they differ from primary tumors in growth patterns and treatment approaches, with focus on surgical resection to alleviate neurological symptoms. The presentation accentuates the importance of genomic testing, multidisciplinary approaches, and considering patients' frailty and prognosis. Dr. Adamson encourages consultation with specialized neuro-oncologists and emphasizes the growing potential for personalized treatments targeting genetic mutations.

Keywords

glioblastoma

genomic analysis

tumor treating fields

Gamma Tile

neuro-oncologists

personalized treatments